For the Media
Dr. Celestia Higano is a member of Fred Hutch's Clinical Research Division. She is a medical oncologist specializing in prostate cancer. Higano is a pioneer in testing therapeutic vaccines against prostate cancer, including a drug known as Provenge, whose FDA approval in 2010 made it the first approved therapeutic vaccine for any solid tumor cancer. She is also focused on immunotherapies for solid tumors.
Overview of Celestia Higano's Research
Stem cell engraftment in MHC-matched and mismatched transplants: development of nonmyeloablative conditioning regimens
Celestia Higano - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Celestia Higano - Seattle Cancer Care Alliance profile
Dr. Higano is a medical oncologist who specializes in treating prostate, bladder and testicular cancers.
Celestia Higano - UW Medicine Profile
Dr. Higano's research interests are therapeutic vaccines, immunotherapy, paliative care, sexual rehabiliatiosn and adnrogen deprivation therapy. She is a pioneer in testing therapeutic vaccines.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.